A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens.

Chevalier, Rachel; Attard, Thomas; Van Driest, Sara L; Shakhnovich, Valentina

Chevalier, Rachel; Attard, Thomas; Van Driest, Sara L; Shakhnovich, Valentina.

Affiliation

Chevalier R; University of Missouri School of Medicine, Kansas, MO, USA.
Attard T; Children's Mercy Kansas City, Division of Gastroenterology, Hepatology and Nutrition, Kansas City, MO, USA.
Van Driest SL; University of Missouri School of Medicine, Kansas, MO, USA.
Shakhnovich V; Children's Mercy Kansas City, Division of Gastroenterology, Hepatology and Nutrition, Kansas City, MO, USA.

Expert Opin Drug Metab Toxicol ; 19(2): 53-56, 2023 02.

Article in En | MEDLINE | ID: mdl-36919492

Subject(s)

Pharmacogenetics; Proton Pump Inhibitors; Humans; Proton Pump Inhibitors/adverse effects; Cytochrome P-450 CYP2C19/genetics; Genotype

Key words

CYP2C19; Proton pump inhibitors; adverse events; gastroesophageal reflux disease (GERD); interstitial nephritis; pharmacogenetics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmacogenetics / Proton Pump Inhibitors Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Expert Opin Drug Metab Toxicol Journal subject: METABOLISMO / TOXICOLOGIA Year: 2023 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google